AIMS: HtrA1 is a member of the HtrA (high-temperature requirement factor A) family of serine proteases. HtrA1 plays a protective role in various malignancies due to its tumour suppressive properties. The aim of this study was to determine HtrA1 expression as a predictor of chemoresponse in patients with advanced gastric cancer. METHODS AND RESULTS: HtrA1 expression was determined by immunohistochemistry on specimens of primary gastric cancer from 80 patients treated consecutively with cisplatin-based combination chemotherapy. Response to chemotherapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Our population consisted of males/females [51/29; median age 64 years (range 32-82)]. A complete or partial response was observed in 71.4% [95% confidence interval (CI) 54.7-88.2], 66.7% (95% CI 47.8-85.5) and 28.6% (95 CI 11.8-45.3) of tumours showing high, medium and low HtrA1 expression, respectively. A statistically significant association between HtrA1 expression and the clinical response was observed (P = 0.002). The median overall survival for patients with high/medium expression was 17 months compared to 9.5 months for patients with low HtrA1 expression (P = 0.037). CONCLUSIONS: Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies. Further assessment of HtrA1 expression is highly warranted in large, prospective studies.
AIMS: HtrA1 is a member of the HtrA (high-temperature requirement factor A) family of serine proteases. HtrA1 plays a protective role in various malignancies due to its tumour suppressive properties. The aim of this study was to determine HtrA1 expression as a predictor of chemoresponse in patients with advanced gastric cancer. METHODS AND RESULTS:HtrA1 expression was determined by immunohistochemistry on specimens of primary gastric cancer from 80 patients treated consecutively with cisplatin-based combination chemotherapy. Response to chemotherapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Our population consisted of males/females [51/29; median age 64 years (range 32-82)]. A complete or partial response was observed in 71.4% [95% confidence interval (CI) 54.7-88.2], 66.7% (95% CI 47.8-85.5) and 28.6% (95 CI 11.8-45.3) of tumours showing high, medium and low HtrA1 expression, respectively. A statistically significant association between HtrA1 expression and the clinical response was observed (P = 0.002). The median overall survival for patients with high/medium expression was 17 months compared to 9.5 months for patients with low HtrA1 expression (P = 0.037). CONCLUSIONS: Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies. Further assessment of HtrA1 expression is highly warranted in large, prospective studies.
Authors: Ning Wang; Kristin A Eckert; Ali R Zomorrodi; Ping Xin; Weihua Pan; Debra A Shearer; Judith Weisz; Costas D Maranus; Gary A Clawson Journal: PLoS One Date: 2012-06-26 Impact factor: 3.240
Authors: Anna Lehner; Viktor Magdolen; Tibor Schuster; Matthias Kotzsch; Marion Kiechle; Alfons Meindl; Fred C G J Sweep; Paul N Span; Eva Gross Journal: PLoS One Date: 2013-04-08 Impact factor: 3.240
Authors: Victoria Gonzalo; Juan Jose Lozano; Virginia Alonso-Espinaco; Leticia Moreira; Jenifer Muñoz; Maria Pellisé; Sergi Castellví-Bel; Xavier Bessa; Montserrat Andreu; Rosa M Xicola; Xavier Llor; Clara Ruiz-Ponte; Angel Carracedo; Rodrigo Jover; Antoni Castells; Francesc Balaguer Journal: PLoS One Date: 2014-03-18 Impact factor: 3.240
Authors: Sisi Wang; Hongyong Zhang; Tiffany M Scharadin; Maike Zimmermann; Bin Hu; Amy Wang Pan; Ruth Vinall; Tzu-yin Lin; George Cimino; Patrick Chain; Momchilo Vuyisich; Cheryl Gleasner; Kim Mcmurry; Michael Malfatti; Kenneth Turteltaub; Ralph de Vere White; Chong-xian Pan; Paul T Henderson Journal: PLoS One Date: 2016-01-22 Impact factor: 3.240
Authors: Dorota Zurawa-Janicka; Jarek Kobiela; Tomasz Slebioda; Rafal Peksa; Marcin Stanislawowski; Piotr Mieczyslaw Wierzbicki; Tomasz Wenta; Barbara Lipinska; Zbigniew Kmiec; Wojciech Biernat; Andrzej Jacek Lachinski; Zbigniew Sledzinski Journal: Int J Mol Sci Date: 2020-05-31 Impact factor: 5.923